pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma
Source abstract
Abstract
This study designs a pH-sensitive nanoparticle carrier of methotrexate (MTX) and combretastatin A4 (CA4) based on pullulan for the combination therapy against hepatocellular carcinoma (HCC). Briefly, N-urocanyl pullulan (URPA) with the degree of substitution (DS) of 5.2% was synthesized and then conjugated with MTX to form MTX-URPA, in which MTX content was 17.8%. MTX-URPA nanoparticles prepared by the dialysis method had spherical shape and the mean size of 187.1 nm, and showed high affinity for HepG2 cells. CA4 was successfully loaded into MTX-URPA nanoparticles and exhibited pH-sensitive in vitro release property. After intravenous injection to PLC/PRF/5-bearing nude mice, CA4 loaded MTX-URPA (CA4/MTX-URPA) nanoparticles achieved the enhanced antitumor and anti-angiogenic effects, the prolonged circulation time in blood, and the increased distributions both in the liver and the tumor. In conclusion, this drug carrier system has significant liver-targeting property and exhibits advantages for the combination therapy against hepatocellular carcinoma.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Hepatocellular Carcinoma Treatment and Prognosis · Multiple Myeloma Research and Treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (44)
Show source-provided references
1. Rising incidence of hepatocellular carcinoma in the United States10.1056/NEJM199903113401001 ↗
2. Hepatocellular carcinoma: from gene to public health10.1093/jnci/89.24.1844 ↗
3. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver10.1016/S0168-8278(01)00130-1 ↗
4. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival10.1053/jhep.2003.50047 ↗
5. Angiogenesis and tumor metastasis10.1146/annurev.med.49.1.407 ↗
6. Angiogenesis and hepatocellular carcinoma10.1016/j.jhep.2004.09.006 ↗
7. Role of angiogenesis in hepatitis and hepatocellular carcinoma
8. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma10.1016/j.canlet.2006.01.008 ↗
9. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results
10. Combination of antiangiogenesis with chemotherapy for more effective cancer treatment10.1158/1535-7163.MCT-08-0715 ↗
11. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy10.1158/0008-5472.CAN-04-1668 ↗
12. Antiangiogenic therapy and tumor progression10.1016/S1535-6108(03)00336-2 ↗
13. Expression of hypoxia-inducible factor 1alpha and vascular endothelial growth factor in hepatocellular carcinoma: impact on neovascularization and survival10.3748/wjg.v11.i11.1705 ↗
14. Involvement of hypoxia-inducible factor-1-alpha in multidrug resistance induced by hypoxia in HepG2 cells
15. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy10.1038/nm0901-987 ↗
16. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy10.1126/science.1104819 ↗
17. Normalization of the vasculature for treatment of cancer and other diseases10.1152/physrev.00038.2010 ↗
18. Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment10.1158/1541-7786.MCR-06-0002 ↗
19. Epidermal growth factor receptor inhibition modulates the microenvironment by vascular normalization to improve chemotherapy and radiotherapy efficacy10.1371/journal.pone.0006539 ↗
20. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system10.1038/nature03794 ↗
21. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature10.1016/j.nano.2011.05.003 ↗
22. Evidence for receptor-mediated hepatic uptake of pullulan in rats10.1016/S0168-3659(00)00368-0 ↗
23. Uptake of pullulan in cultured rat liver parenchymal cells10.1248/bpb.28.560 ↗
24. Liver targeting of plasmid DNA with a cationized pullulan for tumor suppression10.1166/jnn.2006.466 ↗
25. Liver-targeted siRNA delivery by polyethylenimine (PEI)-pullulan carrier10.1016/j.bmc.2010.04.031 ↗
26. Liver targeting of human interferon-beta with pullulan based on metal coordination10.1016/S0168-3659(02)00197-9 ↗
27. Liver targeting of interferon-beta with a liver-affinity polysaccharide based on metal coordination in mice10.1016/S0022-3565(24)29442-8 ↗
28. Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver10.1089/107999099314225 ↗
29. Liver targeting of interferon through pullulan conjugation10.1023/A:1016037225728 ↗
30. Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin10.1021/bi00443a031 ↗
31. Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice10.1038/sj.cgt.7701116 ↗
32. Efficient gene delivery by urocanic acid-modified chitosan10.1016/j.jconrel.2003.08.017 ↗
33. Urocanic acid-modified chitosan-mediated p53 gene delivery inducing apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its antitumor effect in vitro and in vivo10.1016/j.bbrc.2008.10.023 ↗
34. Involvement of endothelial PECAM-1/CD31 in angiogenesis
35. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma10.1056/NEJM199101033240101 ↗
36. Sodium dodecyl sulphate-enhanced desorption of atrazine: effect of surfactant concentration and of organic matter content of soils10.1016/S0045-6535(99)00503-2 ↗
37. Structural characteristics of size-controlled self-aggregates of deoxycholic acid-modified chitosan and their application as a DNA delivery carrier10.1021/bc015510c ↗
38. Aggregation of hydrophobically modified polysaccharides in solution and at the air-water interface10.1016/j.jcis.2004.08.094 ↗
39. Self-assembled nanoparticles of cholesterol-modified O-carboxymethyl chitosan as a novel carrier for paclitaxel10.1088/0957-4484/19/14/145101 ↗
40. Pharmacokinetics and biodistribution of nanoparticles10.1021/mp800049w ↗
41. Factors affecting the clearance and biodistribution of polymeric nanoparticles10.1021/mp800051m ↗
42. Stability and in vivo evaluation of pullulan acetate as a drug nanocarrier10.3109/10717544.2010.490250 ↗
43. Self-assembled cationic nanogels for intracellular protein delivery10.1021/bc700422s ↗
44. Pullulan acetate nanoparticles prepared by solvent diffusion method for epirubicin chemotherapy10.1016/j.colsurfb.2008.12.039 ↗